1. Home
  2. CFND vs BCTX Comparison

CFND vs BCTX Comparison

Compare CFND & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

HOLD

Current Price

$3.44

Market Cap

23.8M

Sector

N/A

ML Signal

HOLD

Logo BriaCell Therapeutics Corp.

BCTX

BriaCell Therapeutics Corp.

HOLD

Current Price

$3.95

Market Cap

26.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
BCTX
Founded
N/A
2014
Country
Canada
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8M
26.6M
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
CFND
BCTX
Price
$3.44
$3.95
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$40.00
AVG Volume (30 Days)
36.6K
167.1K
Earning Date
N/A
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$380.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.85
$0.61
52 Week High
$9.67
$14.68

Technical Indicators

Market Signals
Indicator
CFND
BCTX
Relative Strength Index (RSI) 54.30 66.93
Support Level $3.18 $3.66
Resistance Level $3.53 $4.51
Average True Range (ATR) 0.19 0.26
MACD 0.04 0.12
Stochastic Oscillator 74.60 94.59

Price Performance

Historical Comparison
CFND
BCTX

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Share on Social Networks: